No Picture
News

Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer

SAN DIEGO, April 29, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced… […]

No Picture
News

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

– Developing Oral Therapies with Best-in-Class Potential — Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis — Proceeds of approximately USD 30 million from concurrent financ… […]

No Picture
News

DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company’s Scientific Advisory Board

Dr. Napoleone Ferrara, a Member of DelMar Pharmaceuticals Board Will Serve as the Chairman of the SAB

VANCOUVER, British Columbia and MENLO PARK, Calif., April 4, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Comp… […]

No Picture
News

Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services’ Global Leadership Team as Vice President of Sales and Marketing

SAN DIEGO and WETTEREN, Belgium, April 3, 2019 /PRNewswire/ — Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Jean-Bapti… […]